|
所属 |
附属病院 精神科 |
|
研究室住所 |
秋田市本道1-1-1秋田大学医学部医学系研究科精神科学講座 |
|
研究室電話 |
018-884-6122 |
伊藤 結生 (イトウ ユウ)
ITOH Yu
|
|
|
研究等業績 【 表示 ／ 非表示 】
-
Exploratory Validation of Sleep-Tracking Devices in Patients with Psychiatric Disorders
Masaya Ogasawara, Masahiro Takeshima, Shumpei Kosaka, Aya Imanishi, Yu Itoh, Dai Fujiwara, Kazuhisa Yoshizawa, Norio Ozaki, Kazuyuki Nakagome, Kazuo Mishima
Nat Sci Sleep 2023年04月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database.
Masahiro Takeshima, Minori Enomoto, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Kazuhisa Yoshizawa , Dai Fujiwara , Yoshikazu Takaesu , Kazuo Mishima
Psychiatry Clin Neurosci 2022年09月 [査読有り]
研究論文（学術雑誌） 単著
-
Associations between the 2011 Great East Japan Earthquake and Tsunami and the sleep and mental health of Japanese people: A 3-wave repeated survey
伊藤 結生,竹島 正浩 ,兼板 佳孝,内村 直尚,井上 雄一,本多 真,山寺 亘,渡辺 範雄,北村 真吾,岡島 義,綾部 直子,野村 恭子,三島 和夫
Nature and Science of Sleep 2022年01月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Severity of Depressive Symptoms is Associated with Venous Thromboembolism in Hospitalized Patients with a Major Depressive Episode
Kazuhisa Yoshizawa, Masahiro Takeshima, Sayaka Ishino, Masaya Ogasawara, Dai Fujiwara, Yu Itoh, Aya Imanishi, Hidenobu Ohta, Kazuo Mishima
Neuropsychiatr Dis Treat 2021年09月 [査読有り]
研究論文（学術雑誌） 国内共著
-
The Usefulness of the Combination of D-Dimer and Soluble Fibrin Monomer Complex for Diagnosis of Venous Thromboembolism in Psychiatric Practice: A Prospective Study
Masahiro Takeshima, Hiroyasu Ishikawa, Masaya Ogasawara, Munehiro Komatsu, Dai Fujiwara, Yu Itoh, Yuki Wada, Yuki Omori, Hidenobu Ohta, Kazuo Mishima
Vasc Health Risk Manag 2021年05月 [査読有り]
研究論文（学術雑誌） 国内共著
-
増大号特集 睡眠の正しい理解を促す70のトリビア Ⅲ章 睡眠に関連する病態 Q37 不眠症だと認知症になりやすいのでしょうか? 不眠症の治療で認知症を予防できるのでしょうか?
伊藤 結生, 竹島 正浩
精神医学 ( 株式会社医学書院 ) 67 ( 5 ) 683 - 686 2025年05月
-
Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan
Masahiro Takeshima, Kazuhisa Yoshizawa, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Naoko Ayabe, Kazuo Mishima
JAMA Network Open ( American Medical Association (AMA) ) 7 ( 4 ) e246865 2024年04月
<jats:sec id="ab-zoi240266-4"><jats:title>Importance</jats:title><jats:p>Although insomnia guidelines recommend the use of several individual hypnotics, the most useful hypnotic for treating insomnia in a clinical setting remains unclear.</jats:p></jats:sec><jats:sec id="ab-zoi240266-5"><jats:title>Objective</jats:title><jats:p>To determine which guideline-recommended hypnotics have lower risks of monotherapy failure and which hypnotics have a higher risk of long-term prescription for insomnia treatment.</jats:p></jats:sec><jats:sec id="ab-zoi240266-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This retrospective observational cohort study used data from the Japan Medical Data Center Claims Database from April 1, 2005, to March 31, 2021. Participants included adults whose first prescribed pharmaceutical treatment for insomnia was guideline-recommended hypnotic monotherapy. Data were analyzed from December 24, 2022, to September 26, 2023.</jats:p></jats:sec><jats:sec id="ab-zoi240266-7"><jats:title>Exposures</jats:title><jats:p>Suvorexant, ramelteon, eszopiclone, zolpidem, and triazolam monotherapy.</jats:p></jats:sec><jats:sec id="ab-zoi240266-8"><jats:title>Main Outcomes and Measures</jats:title><jats:p>The primary outcome was monotherapy failure, defined as a change in hypnotic or having an additional hypnotic prescribed for insomnia within 6 months of the first prescription of a guideline-recommended hypnotic monotherapy. The secondary outcome was monotherapy discontinuation, defined as no prescription of any hypnotic for 2 consecutive months within 6 months after prescribing a guideline-recommended hypnotic in patients for whom monotherapy did not fail. Monotherapy failure and discontinuation were compared using Cox proportional hazards and logistic regression models, respectively.</jats:p></jats:sec><jats:sec id="ab-zoi240266-9"><jats:title>Results</jats:title><jats:p>The study included 239 568 adults (median age, 45 [IQR, 34-55] years; 50.2% women) whose first prescription for insomnia was guideline-recommended hypnotic monotherapy. During the 6-month follow-up period, 24 778 patients (10.3%) experienced failure of monotherapy with a guideline-recommended hypnotic. In comparison with eszopiclone, there were more cases of monotherapy failure for ramelteon (adjusted hazard ratio [AHR], 1.23 [95% CI], 1.17-1.30; <jats:italic>P</jats:italic> &lt; .001), fewer cases for zolpidem (AHR, 0.84 [95% CI, 0.81-0.87]; <jats:italic>P</jats:italic> &lt; .001) and triazolam (AHR, 0.82 [95% CI, 0.78-0.87]; <jats:italic>P</jats:italic> &lt; .001), and no significant difference between suvorexant and eszopiclone. Among those without monotherapy failure, monotherapy was discontinued in 84.6% of patients, with more discontinuations for ramelteon (adjusted odds ratio [AOR], 1.31 [95% CI, 1.24-1.40]; <jats:italic>P</jats:italic> &lt; .001) and suvorexant (AOR, 1.20 [95% CI, 1.15-1.26]; <jats:italic>P</jats:italic> &lt; .001) than for eszopiclone and no significant difference between zolpidem or triazolam and eszopiclone.</jats:p></jats:sec><jats:sec id="ab-zoi240266-10"><jats:title>Conclusions and Relevance</jats:title><jats:p>Due to uncontrolled confounding factors in this cohort study, no conclusions regarding the pharmacologic properties of guideline-recommended hypnotics can be drawn based on these results. Further studies accounting for confounding factors, including diagnoses of chronic vs acute insomnia disorder, insomnia and psychiatric symptom severity, and physician attitudes toward hypnotic prescription, are needed.</jats:p></jats:sec>
-
Effects of Japanese policies and novel hypnotics on long‐term prescriptions of hypnotics
Masahiro Takeshima, Kazuhisa Yoshizawa, Minori Enomoto, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Naoko Ayabe, Yoshikazu Takaesu, Kazuo Mishima
Psychiatry and Clinical Neurosciences ( Wiley ) 77 ( 5 ) 264 - 272 2023年01月
<jats:sec><jats:title>Aim</jats:title><jats:p>The current study aimed to examine the effect of Japanese policies for appropriate hypnotics use and novel hypnotics (e.g. melatonin receptor agonist and orexin receptor antagonist [ORA]) on long‐term prescriptions of hypnotics.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This retrospective study was conducted using a large‐scale health insurance claims database. Among subscribers prescribed hypnotics at least once between April 2005 and March 2021, those prescribed hypnotics for the first time after being included in the database in three periods (period 1: April 2012–March 2013; period 2: April 2016–March 2017; and period 3: April 2018–March 2019) were eligible. These were set considering the timing of the 2014 and 2018 medical fee revisions (2014 for polypharmacy of three or more hypnotics, 2018 for long‐term prescription of benzodiazepine receptor agonists for >12 months). The duration of consecutive prescriptions of hypnotics over 12 months was evaluated. Factors associated with short‐term prescriptions of hypnotics were also investigated.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In total, 186 535 participants were newly prescribed hypnotics. The mean duration of prescriptions was 2.9 months, and 9.3% of participants were prescribed hypnotics for 12 months. Prescription periods were not associated with short‐term prescriptions of hypnotics. ORA use was associated with short‐term prescriptions of hypnotics (adjusted hazard ratio, 1.077 [95% confidence interval, 1.035–1.120]; <jats:italic>P</jats:italic> < 0.001), but melatonin receptor agonist use was not.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Japanese policies had no statistically significant effect on long‐term prescriptions of hypnotics. Although this study suggests initiating ORA for insomniacs as a candidate strategy to prevent long‐term prescriptions of hypnotics, further research is necessary to draw conclusions.</jats:p></jats:sec>
-
伊藤 結生, 綾部 直子, 三島 和夫
精神医学 ( 株式会社医学書院 ) 64 ( 3 ) 333 - 340 2022年03月
-
Prevalence of asymptomatic venous thromboembolism in depressive inpatients
Takeshima M.
Neuropsychiatric Disease and Treatment ( Neuropsychiatric Disease and Treatment ) 16 579 - 587 2020年